---
layout: post
title: "Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Availability"
date: 2026-02-05 18:58:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-28092
original_published: 2023-12-21 00:00:00 +0000
significance: 8.00
---

# Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** December 21, 2023 00:00 UTC
**Document Number:** 2023-28092

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization." This guidance provides recommendations to sponsors on the development of monoclonal antibody products targeting SARS-CoV-2 intended for the prevention or treatment of COVID- 19, including addressing the impact of emerging variants. The recommendations focus on the data and information that may be used to support a request for emergency use authorization (EUA) under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance supersedes the guidance entitled "Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency" issued on February 22, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/12/21/2023-28092/development-of-monoclonal-antibody-products-targeting-sars-cov-2-for-emergency-use-authorization)
- API: https://www.federalregister.gov/api/v1/documents/2023-28092

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
